Preferred Label : Crizotinib;
MeSH definition : A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE
KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR
(HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.;
MeSH hyponym : PF-2341066; PF 2341066; PF2341066; PF 02341066; PF02341066;
MeSH CAS label : 2-Pyridinamine, 3-((1R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-5-(1-(4-piperidinyl)-1H-pyrazol-4-yl)-;
Wikipedia link : https://en.wikipedia.org/wiki/Crizotinib;
UNII : 53AH36668S;
Origin ID : D000077547;
UMLS CUI : C2974289;
ATC code(s)
- Allowable qualifiers
- Automatic exact mappings (from CISMeF team)
- CISMeF manual mappings
- Pharmacological action(s)
- Record concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
A piperidine and aminopyridine derivative that acts as an inhibitor of RECEPTOR PROTEIN-TYROSINE
KINASES, including ANAPLASTIC LYMPHOMA KINASE (ALK) and HEPATOCYTE GROWTH FACTOR RECEPTOR
(HGFR; c-Met). It is used in the treatment of NON-SMALL CELL LUNG CANCER.
https://ansm.sante.fr/tableau-marr/crizotinib
2024
false
false
false
France
French
patients guideline
patient education handout
drug information
risk management
Crizotinib
Crizotinib
continuity of patient care
crizotinib
vision disorders
adult
child
---
https://www.has-sante.fr/jcms/p_3444785/fr/xalkori-crizotinib-lymphome-anaplasique-a-grandes-cellules-lagc
2023
false
false
false
France
French
treatment outcome
child
insurance, health, reimbursement
administration, oral
Crizotinib
crizotinib
evaluation of the transparency committee
adolescent
Refractory Systemic Anaplastic Large Cell Lymphoma, ALK-Positive
Recurrent Systemic Anaplastic Large Cell Lymphoma, ALK-Positive
antineoplastic agents
protein kinase inhibitors
lymphoma, large-cell, anaplastic
---
https://www.has-sante.fr/jcms/p_3428384/fr/xalkori-crizotinib-lymphome-t-anaplasique-a-grandes-cellules-lagc-pediatrie
2023
false
false
false
France
child
treatment outcome
insurance, health, reimbursement
antineoplastic agents
crizotinib
guidelines for drug use
administration, oral
Childhood Anaplastic Large Cell Lymphoma, ALK-Positive
recurrence
protein kinase inhibitors
evaluation of the transparency committee
lymphoma, large-cell, anaplastic
Crizotinib
---
https://ansm.sante.fr/tableau-acces-derogatoire/xalkori
2023
false
false
false
France
French
drug information
administration, oral
Crizotinib
antineoplastic agents
protein kinase inhibitors
capsules
pharmaceutical solutions
child
infant
lymphoma, large-cell, anaplastic
Childhood Anaplastic Large Cell Lymphoma, ALK-Positive
crizotinib
MET Exon 14 Mutation
Locally Advanced Lung Non-Small Cell Carcinoma
adult
Metastatic Lung Non-Small Cell Carcinoma
carcinoma, non-small-cell lung
continuity of patient care
---
https://www.has-sante.fr/jcms/p_3442461/fr/xalkori-crizotinib-tumeurs-myofibroblastiques-inflammatoires-tmi
2023
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
Crizotinib
crizotinib
Inflammatory Myofibroblastic Tumor
antineoplastic agents
protein kinase inhibitors
child
adolescent
Childhood Inflammatory Myofibroblastic Tumor
soft tissue neoplasms
ALK Positive
administration, oral
---
https://www.has-sante.fr/jcms/p_3359507/fr/xalkori-crizotinib-lymphome-t-anaplasique-a-grandes-cellules-lagc
https://www.has-sante.fr/jcms/p_3359522/fr/decision-n2022-0280/dc/sem-du-21-juillet-2022-du-college-de-la-haute-autorite-de-sante-portant-autorisation-d-acces-precoce-de-la-specialite-xalkori
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
crizotinib
administration, oral
protein kinase inhibitors
child
adolescent
recurrence
Childhood Anaplastic Large Cell Lymphoma, ALK-Positive
Recurrent Childhood Anaplastic Large Cell Lymphoma
Refractory Anaplastic Large Cell Lymphoma
ALK Fusion Protein Expression
guidelines for drug use
evaluation of the transparency committee
Crizotinib
lymphoma, large-cell, anaplastic
---
https://ansm.sante.fr/informations-de-securite/xalkori-crizotinib-troubles-de-la-vision-incluant-un-risque-de-perte-de-vision-severe-et-necessite-de-surveillance-des-patients-pediatriques
2022
false
false
false
France
French
pharmacovigilance note
Crizotinib
crizotinib
vision disorders
continuity of patient care
blindness
child
risk
vision screening
vision disorders
vision disorders
---
https://www.has-sante.fr/jcms/p_3181549/fr/xalkori
2020
false
false
false
France
crizotinib
treatment outcome
insurance, health, reimbursement
protein kinase inhibitors
adult
proto-oncogene proteins c-met
MET Exon 14 Mutation
neoplasm metastasis
carcinoma, non-small-cell lung
carcinoma, non-small-cell lung
administration, oral
mutation
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
protein-tyrosine kinases
Crizotinib
---
https://www.has-sante.fr/jcms/p_3184923/fr/xalkori
2020
false
false
false
France
crizotinib
protein kinase inhibitors
protein-tyrosine kinases
adult
treatment outcome
carcinoma, non-small-cell lung
insurance, health, reimbursement
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
Crizotinib
---
https://www.has-sante.fr/portail/jcms/c_2779442/fr/xalkori-crizotinib-inhibiteur-de-tyrosine-kinase
https://www.has-sante.fr/portail/jcms/c_2779442/fr/xalkori
2017
false
France
French
ROS1 Gene Rearrangement
ROS1 protein, human
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
crizotinib
administration, oral
protein kinase inhibitors
protein kinase inhibitors
carcinoma, non-small-cell lung
protein-tyrosine kinases
treatment outcome
survival analysis
insurance, health, reimbursement
carcinoma, non-small-cell lung
protein-tyrosine kinases
proto-oncogene proteins
Crizotinib
Crizotinib
---
http://www.e-cancer.fr/Expertises-et-publications/Catalogue-des-publications/Medicaments-ciblant-ALK-crizotinib-ceritinib
2016
false
false
false
France
French
guidelines for drug use
protein kinase inhibitors
crizotinib
carcinoma, non-small-cell lung
ceritinib
ceritinib
receptor Protein-Tyrosine kinases
antineoplastic agents
administration, oral
protein kinase inhibitors
ceritinib
Drug-Related side effects and adverse reactions
continuity of patient care
drug interactions
interdisciplinary communication
risk factors
drug monitoring
ceritinib
carcinoma, non-small-cell lung
ALK gene rearrangement positive
ALK protein, human
patients guideline
practice guideline
Tyrosine Kinase Inhibitors
pyrimidines
sulfones
pyrimidines
sulfones
pyrimidines
sulfones
receptor Protein-Tyrosine kinases
Crizotinib
Crizotinib
Crizotinib
Anaplastic Lymphoma Kinase
---
http://www.has-sante.fr/portail/jcms/c_1543504/fr/xalkori
2013
false
France
French
Tyrosine Kinase Inhibitors
evaluation of the transparency committee
crizotinib
administration, oral
protein kinase inhibitors
protein kinase inhibitors
carcinoma, non-small-cell lung
protein-tyrosine kinases
treatment outcome
survival analysis
insurance, health, reimbursement
carcinoma, non-small-cell lung
receptor Protein-Tyrosine kinases
Crizotinib
Crizotinib
Anaplastic Lymphoma Kinase
---
http://www.meddispar.fr/Medicaments/XALKORI-250-B-60/(type)/letter/(value)/X/(cip)/3400926762797
2013
false
France
French
drug information
administration, oral
drug prescriptions
legislation, drug
continuity of patient care
drug monitoring
crizotinib
pyrazoles
pyridines
Crizotinib
---
Summary Basis of Decision (SBD) for Xalkori
Crizotinib, 200 mg and 250 mg, Capsule, Oral
https://hpr-rps.hres.ca/reg-content/sommaire-motif-decision-detailOne.php?lang=fr&linkID=SBD00312
2012
false
Canada
French
English
drug evaluation
Tyrosine Kinase Inhibitors
drug approval
canada
administration, oral
crizotinib
protein kinase inhibitors
protein kinase inhibitors
receptor Protein-Tyrosine kinases
carcinoma, non-small-cell lung
neoplasm metastasis
treatment outcome
clinical trials as topic
drug interactions
survival analysis
risk assessment
Crizotinib
Crizotinib
Anaplastic Lymphoma Kinase
---
https://www.ema.europa.eu/medicines/human/EPAR/Xalkori
2012
false
United Kingdom
French
English
Tyrosine Kinase Inhibitors
crizotinib
administration, oral
drug approval
treatment outcome
carcinoma, non-small-cell lung
summary of product characteristics
package leaflet
syndication feed
adult
carcinoma, non-small-cell lung
receptor Protein-Tyrosine kinases
protein kinase inhibitors
protein kinase inhibitors
aged
drug interactions
pregnancy
breast feeding
fertility
receptor Protein-Tyrosine kinases
drug evaluation, preclinical
Crizotinib
Crizotinib
Anaplastic Lymphoma Kinase
---
